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CONTRIBUTION
What are the novel findings of this work?
Our study found no evidence of substantial harm, in terms
of neurodevelopment and health, in offspring exposed
to progesterone in the second and third trimesters of
pregnancy.
What are the clinical implications of this work?
This work contributes to data that are needed to build
reliable evidence on the long-term safety of in-utero
exposure to progesterone, information that is crucial
when counseling pregnant women with an indication for
progesterone use.
ABSTRACT
Objective To evaluate the long-term outcomes of children
born to women with a short cervix and otherwise low
risk for preterm birth, after antenatal exposure to vaginal
progesterone vs placebo.
Methods This was a follow-up study of the Triple P trial,
which randomized 80 low-risk women with a short cervix
(≤ 30 mm) at 18–22 weeks’ gestation to progesterone
(n = 41) or placebo (n = 39). At 2 years of corrected
age, children were invited for a neurodevelopmental
assessment, using the Bayley Scales of Infant and Toddler
Development, third edition (BSID-III), and a neurological
and physical examination by an assessor blinded to the
allocated treatment. Parents filled out the Ages and Stages
Questionnaire, the Child Behavior Checklist (CBCL)
and a general-health questionnaire. The main outcome
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of interest was mean BSID-III cognitive and motor
scores. Additionally, a composite score of mortality and
abnormal developmental outcome, including BSID-III
≤–1 SD, CBCL score in the clinical range and/or parental
reported physical problems (at least two operations or at
least two hospital admissions in the previous 2 years), was
evaluated. Our sample size, dictated by the original sample
of the Triple P trial, provided 80% power to detect a mean
difference (MD) of 15 points (1 SD) between groups for
the BSID-III tests.
Results Of the 80 children born to the randomized
women, one in the progesterone group and two in the
placebo group died in the neonatal period. Follow-up data
were obtained for 59/77 (77%) children and BSID-III
outcomes in 57 children (n = 28 in the progesterone
group and n = 29 in the placebo group) born at a median
gestational age of 38 + 6 weeks (interquartile range (IQR),
37 + 3 to 40 + 1 weeks) with a median birth weight
of 3240 g (IQR, 2785–3620 g). In the progesterone vs
placebo groups, mean BSID-III cognitive development
scores were 101.6 vs 105.0 (MD, –3.4 (95% CI, –9.3
to 2.6); P = 0.29) while mean motor scores were 102.4
vs 107.3 (MD, –4.9 (95% CI, –11.2 to 1.4); P = 0.13).
No differences were seen between the two groups in
physical (including genital and neurological examination),
behavioral and health-related outcomes.
Conclusion In this sample of children born to low-risk
women with a short cervix at screening, no relevant differ-
ences in neurodevelopmental, behavioral, health-related
and physical outcomes were found between offspring
exposed to vaginal progesterone and those exposed to
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placebo. © 2020 The Authors. Ultrasound in Obstetrics
& Gynecology published by John Wiley & Sons Ltd on
behalf of International Society of Ultrasound in Obstetrics
and Gynecology.
INTRODUCTION
Preterm birth (PTB) is associated with increased rates
of neonatal mortality and long-term morbidity1. The
prevention of PTB would therefore substantially benefit
infant health and reduce healthcare costs. Women with a
short cervix (≤ 30 mm) have a 3- to 4-fold increased risk
of PTB2. An individual-patient data (IPD) meta-analysis
evaluating the effect of vaginal progesterone vs placebo
in 974 women with a singleton pregnancy with a cervical
length ≤ 25 mm, showed a reduction in the rate of
PTB before 33 weeks’ gestation from 22% to 14%
(relative risk (RR), 0.62 (95% CI, 0.47–0.81))3. This IPD
meta-analysis concluded that there is no evidence that
vaginal progesterone has adverse effects on childhood neu-
rodevelopmental outcomes3. However, this conclusion is
based on the follow-up data of five randomized trials with
a follow-up period between 2 and 8 years of age and car-
ried out in high-risk populations (i.e. twin gestation or pre-
vious spontaneous PTB), of which four out of the five stud-
ies used screening instruments (e.g. questionnaires) instead
of in-person developmental examinations4–8. To increase
confidence in the absence of harm of progesterone, more
sensitive in-person developmental examination data are
needed.
Assessment of long-term outcomes is particularly
important, as previous studies have demonstrated that
agents administered to pregnant women with the aim
of improving pregnancy outcomes can have unexpected
long-term effects on children, which may not be apparent
at birth9. Historically, there has been fear of the
possibility of masculinization of the genital tract in
female fetuses or hypospadias in male infants exposed
to progesterone10, but several observational studies have
been unable to confirm or refute these assumptions11–13.
Studying the developmental outcomes after in-utero
exposure to progesterone is important, both in preterm
and term infants. First, animal studies suggest that
progesterone has a substantial impact on the development
of the fetal brain14. It is unknown if the same thing
happens in humans, but one can hypothesize either a
neuroprotective or a deleterious effect by disturbing the
brain maturation processes. Second, neurodevelopmental
impairment is among the most common complications
reported after PTB15; thus, it is reasonable to consider
that if progesterone is able to decrease the severity of
prematurity it could potentially reduce developmental
problems.
In the Triple P trial, 80 women with a short (≤ 30 mm)
cervix on ultrasonography at 18–22 weeks’ gestation, but
otherwise at low risk for PTB, were randomized to receive
progesterone or placebo16. The aim of this follow-up
study was to compare the neurodevelopmental and other
health outcomes of their infants at 2 years of corrected
age using robust diagnostic instruments.
METHODS
The Triple P trial was a multicenter double-blind
placebo-controlled randomized trial on the effectiveness
of vaginal progesterone in reducing adverse neonatal
outcome through a reduction in the rate of PTB
in women with a low-risk pregnancy and a short
cervical length (Registration No: NL1961). The trial
and its follow-up were approved by the Medical Ethics
Committee of the Amsterdam UMC, Academic Medical
Centre, The Netherlands (AMC 08-328), and its protocol,
including the plans for follow-up, was published in
advance17.
The trial was discontinued early owing to the unex-
pectedly low number of women with a short (≤ 30 mm)
sonographic cervix at two independent assessments
performed within a fortnight. Between 2009 and 2013
a total of 20 234 women were screened, of whom 151
were eligible for inclusion and 80 of these agreed to
participate. After providing informed consent, women
were randomized to progesterone (n = 41) or placebo
(n = 39). The study medication was self-administered
vaginally on a daily basis between 22 and 34 weeks’ ges-
tation, using capsules of 200 mg micronized progesterone
or identical-appearing placebo capsules. The primary
outcome measure in the original trial was a composite
of adverse neonatal outcomes until 10 weeks after the
expected date of delivery. Further details are provided in
van Os et al.16. Adverse neonatal outcome occurred in
5% of women in the progesterone group vs 11% in the
control group (RR, 0.47 (95% CI, 0.09–2.4)). PTB before
32 weeks occurred in 2% in the progesterone group vs
8% in the control group (RR, 0.33 (95% CI, 0.04–3.0)).
Although adherence to the study medication was mod-
erate (only 51% used ≥ 80% of the study medication),
exposure to the medication could be up to 12 weeks, as
the majority of the women in the progesterone group
(88%) delivered after 34 weeks’ gestation.
Follow-up assessment
All families with a living child who participated in the
original Triple P trial were contacted by phone 3 months
prior to the corrected age of 2 years, corrected age being
defined as the age calculated from the due date. After
the parents had provided informed consent, the cognitive
and motor development of the infants was assessed using
the cognitive and motor scales of the Bayley Scales of
Infant and Toddler Development, third edition (BSID-III),
followed by a physical and neurological examination.
A trained team of psychologists and medical doctors
performed all Bayley tests at home or in an outpatient
clinic. Parents were asked to fill out the questionnaires
before or shortly after the visit. Parents, psychologists,
pediatricians and researchers involved in data collection
and entry remained blind to the allocated treatment. The
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main outcome of interest in this follow-up study was
mean BSID-III cognitive and motor scores.
The Dutch version of the BSID-III was used to assess
cognitive and motor development18, but we used the
BSID-III norms for children of the US population (mean
of 100 and SD of 15)19, as the Dutch norms were
not yet available. The test and its norms are used
worldwide in healthcare settings, as well as for scientific
research purposes. A score of ≤ 70 represents severe
neurodevelopmental impairment. A score of 70 to ≤ 85
points (i.e. > 1 SD below the mean) for any of the scales
of the BSID-III represents mild impairment and is often
used to identify children in need of intervention.
The parents were asked to complete a general-health
questionnaire comprising sociodemographic character-
istics of the parents and the child and clinical history
of the child after initial discharge from hospital and
up to the age of 2 years, including use of medication,
hospital admissions and need for surgery. Physical and
neurological examination was performed by one of three
medical doctors (A.G.v.W.-L., C.S. and C.J.J.C.) using
a standardized assessment format evaluating vision,
hearing, heart, lung, abdomen, dermal, genital and
neurological abnormalities. Physical abnormalities were
assessed and combined into categories such as congenital
abnormalities, syndromes/genetic disorders and neuro-
logical abnormalities. If more than one abnormality in
one category was found in the same child, this was
counted as one case. Particular attention was given to all
abnormalities in the genital region.
Two validated parental questionnaires were used:
the Ages and Stages Questionnaire (ASQ) third edition
and the Child Behavior Checklist for ages 1.5–5 years
(CBCL)20,21. The ASQ is a developmental screening tool
that covers five domains of child development: com-
munication, gross motor and fine motor development,
problem-solving and personal–social skills. A validated
Dutch translation of the ASQ 24 months was used. ASQ
scores of 1 SD below the normative mean in two or more
domains, or 2 SD below the normative mean in at least
one domain were scored as abnormal, consistent with the
clinical use of the ASQ in The Netherlands22. The ASQ
was added to the protocol in order to gain additional
information on child development from a parental
perspective. The CBCL assesses the parental perception
of social competency and behavioral problems during
the previous 2 months. It informs on eight subscales:
emotionally reactive, anxious or depressed, somatic com-
plaints, withdrawn, sleep problems, attention problems
and aggressive behavior. Data from these subscales can
be summed to provide a combined total-problems score
and two broad-band scale scores (internalizing problems
and externalizing problems). A score > 97th percentile
on any of the subscales or a score > 90th percentile
in one of the two broad-band scales or total-problems
score was defined as abnormal and clinically relevant,
indicating serious behavioral problems (clinical range),
a cut-off that is also consistent with clinical use in
The Netherlands21.
Abnormal scores in any of the three developmental
assessment tools (BSID-III cognitive or motor score
≤–1 SD; CBCL score in the clinical range; or physical
problems defined as the need for two or more operations
or two or more hospital admissions in the 2 years prior
to the assessment) were combined as a binary outcome
of ‘abnormal developmental outcome’. The abnormal
developmental outcome was combined with mortality to
demonstrate the entire spectrum of adverse outcomes from
randomization until follow-up at 2 years of age. Research
nurses in the participating centers cross-checked the med-
ical records of all children who participated in the original
trial to track the possible occurrence of death from birth
until the age of 2 years. This allowed us to obtain largely
reliable mortality data from non-responders as well.
Power calculation
The main outcomes of interest were the BSID-III cognitive
and motor scores. An indicative power calculation showed
that 17 children per group would give 80% power to
find a mean difference of 15 points in the BSID-III scores
(mean of 100 and SD of 1) with a two-sided significance
level of 0.05. Detection of a more subtle (but clinically rel-
evant) difference of 7.5 points in the mean (corresponding
to 0.5 SD) with 80% power would require 64 children
per group. Because the size of the study was predefined by
the number of women recruited to the Triple P trial, the
study was deemed sufficiently powered to demonstrate
a difference of 1 SD in the means in the BSID-III test
between the two groups, but was underpowered to detect
smaller (but clinically relevant) differences.
Statistical analysis
Differences in baseline characteristics of the mothers and
children participating in the Triple P follow-up study
between those who were exposed to vaginal progesterone
and those who were not, as well as differences between
participants in the original trial who participated in this
follow-up study and those who were lost to follow-up,
were compared using the unpaired t-test, Mann–Whitney
U-test, χ-square test or Fisher’s exact test, as appropriate.
Mean cognitive and motor scores of the BSID-III, as
well as the proportion of children with a mild (corre-
sponding to –1 SD or 15 points below the mean) or severe
(corresponding to –2 SD or > 30 points below the mean)
cognitive and motor impairment were calculated. All other
test outcomes (neurological examination, general physical
examination, genital examination, ASQ and CBCL ques-
tionnaires) were reported as binary outcomes. Results of
the general-health questionnaire (providing information
on the need for medical specialist and/or developmental
care, use of medication in the past and present, hospi-
tal admission and need for surgery) were clustered into
binary categories to distinguish between frequent use (e.g.
more than one hospital admission and/or more than
one operation) and ‘normal’ use of healthcare services.
These cut-offs were all predefined before performing the
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analysis, as they have been used by our research team in
previous follow-up studies using the same questionnaire23.
Potential confounders were visualized using a directed
acyclic graph. The graph demonstrated no potential
confounders and therefore no correction was applied
(Figure S1). The unpaired t-test, Mann–Whitney U-test,
χ-square test or Fisher’s exact test was used for
comparison of outcomes between the progesterone and
placebo groups, with a significance level of 0.05 for a
two-tailed test. Analysis was performed according to the
intention-to-treat principle.
For the composite outcome, combining mortality and
abnormal developmental outcome, we used imputed
data for the children that were lost to follow-up. This
was necessary to keep the denominator consistent with
the original sample of the Triple P trial (n = 80). We
imputed all missing outcomes in children that were lost
to follow-up using multiple imputation techniques with
10 datasets using the following variables as predictors:
ethnicity, maternal age, smoking at start of pregnancy,
parental education and neonatal outcomes, comprising
gestational age at birth, birth weight, neonatal sepsis,
infant respiratory distress syndrome, intraventricular
hemorrhage, necrotizing enterocolitis, gender of the
neonate. Odds ratios (ORs) were calculated using
generalized linear models. SPSS version 25 (IBM Inc.,
Armonk, NY, USA) was used for all analyses24.
RESULTS
Of the 80 women and children enrolled in the Triple P
trial (41 in the progesterone group and 39 in the placebo
group), three children (one in the progesterone group and
two in the placebo group) died in the neonatal period
owing to extreme prematurity (median gestational age,
24 + 0 weeks), leaving 77 surviving children eligible for
follow-up. All 77 children were alive at the age of 2 years.
Follow-up data were collected between August 2012 and
December 2015.
Eighteen (23%) children were lost to follow-up, either
because there was no contact information available (seven
in the progesterone group and four in the placebo
group) or they declined further participation (four in
the progesterone group and three in the placebo group).
The pregnancy and neonatal outcomes and background
characteristics of the 59 participants of the follow-up
study were broadly similar to those of the 18 who were
lost to follow-up, except for a higher loss to follow-up
of parents with low-level education (6/18 (33%) vs 11/59
(19%); P < 0.001) and of non-white-European ethnic
origin (10/18 (56%) vs 14/59 (24%); P = 0.01) (Table S1).
Of the 59/77 (77%) children who participated in
the follow-up study, 57/77 (74%) underwent BSID-III
assessment (28 in the progesterone group and 29 in the
placebo group) and 54/77 (70%) underwent a physical
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Figure 1 Flowchart showing participants of original Triple P trial who took part in current follow-up study at corrected age of 2 years.
ASQ, Ages and Stages Questionnaire, third edition; BSID-III, Bayley Scales of Infant and Toddler Development, third edition; CBCL, child
behavior checklist; GHQ, general-health questionnaire.
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a median corrected age of 25 months (interquartile
range (IQR), 23–27 months). Median gestational age at
birth was 38 + 6 weeks (IQR, 37 + 1 to 40 + 2 weeks)
in the progesterone group and 38 + 5 weeks (IQR,
37 + 6 to 40 + 1 weeks) in the placebo group (Table 1).
Other relevant maternal and infant characteristics and
pregnancy and neonatal outcomes were comparable
between the progesterone and placebo groups (Table 1).
Neurodevelopmental outcomes
The mean BSID-III cognitive score did not differ sig-
nificantly between the two groups, being 101.6 in the
progesterone vs 105.0 in the placebo group (mean differ-
ence, –3.4 (95% CI, –9.3 to 2.6); P = 0.29). Similarly, the
BSID-III motor scores did not differ significantly between
the two groups (Table 2). The proportion of children with
a BSID-III score (either cognitive or motor) of ≤–1 SD
was comparable between the two groups (1/28 vs 1/29)
(Table 3). Neurological examination showed no cases of
cerebral palsy, and the occurrence of mild neurological
abnormalities, consisting of mild hypotonia or hypertonia
of the extremities, was low and not statistically signif-
icantly different between the progesterone and placebo
groups (8% vs 4%; RR, 2.00 (95% CI, 0.19–20.67)).
An abnormal CBCL score was found in one child (1/27
(4%)) in the progesterone group and in four (4/27 (15%))
in the placebo group (RR, 0.22 (95% CI, 0.02–2.12)).
The number of children with abnormal ASQ scores was
comparable between the two groups (Table 2).
Physical outcomes
Miscellaneous minor congenital malformations were
twice as frequent in the progesterone group than
in the placebo group, but this difference was not
statistically significant (6/26 (23%) vs 3/26 (12%); RR,
2.0 (95% CI, 0.56–7.16)). This included malformations
Table 1 Pregnancy and neonatal outcomes and sociodemographic characteristics of 57 mothers and their children who participated in Triple
P follow-up study and underwent BSID-III assessment at 2 years of age, according to whether mothers were randomized to progesterone or
placebo in Triple P trial
Parameter Progesterone (n = 28) Placebo (n = 29) P
Maternal characteristics
Age at randomization (years) 31 (26–34) 31 (29–34) 0.46
Nulliparous 22 (79) 18 (62) 0.17
Parental education* 0.94
High 17 (61) 18/28 (64)
Middle 5 (18) 5/28 (18)
Low 6 (21) 5/28 (18)
White European 22 (79) 22 (76) 0.81
Infant characteristics at 2 years
Living in two-parent family† 25 (89) 26/27 (96) 0.51
First-born child 22 (79) 16/27 (59) 0.12
Dutch main language spoken at home 26 (93) 21/27 (78) 0.11
Bilingual 7 (25) 9/27 (33) 0.50
Breastfed for first 6 months‡ 6/27 (22) 9/27 (33) 0.36
Use of day care 19 (68) 18/27 (67) 0.32
Pregnancy outcome
Corticosteroids during pregnancy 5 (18) 5 (17) 0.95
PPROM 4 (14) 3 (10) 0.71
Complied with treatment§ 20 (71) 15/28 (54) 0.21
Neonatal outcome
Male gender 19 (68) 13 (45) 0.08
Composite adverse neonatal outcome¶ 0 (0) 2 (7) 0.49
Admission to NICU 0 (0) 5 (17) 0.05
GA at birth (weeks) 38 + 6 (37 + 1 to 40 + 2) 38 + 5 (37 + 6 to 40 + 1) 0.82
GA at birth < 32 weeks 0 (0) 3 (10) 0.24
GA at birth < 34 weeks 2 (7) 3 (10) 1.00
GA at birth < 37 weeks** 5 (18) 4 (14) 0.73
Birth weight (g) 3013 (2603–3506) 3360 (2915–3755) 0.13
Birth weight < 2500 g 5 (18) 4 (14) 0.73
Birth weight < 1500 g 0 (0) 2 (7) 0.49
Data are given as median (interquartile range), n (%) or n/N (%). *Parental education: ‘low level’ (< 6 total years postelementary schooling)
if at least one parent had a low level of education (but not if one parent had a high level); ‘middle level’ (6–8 total years postelementary
schooling) if both parents had middle level of education; ‘high level’ (> 8 total years of postelementary schooling) if at least one parent was
highly educated. †Two biological parents or one biological and one non-biological parent. ‡Breastfeeding exclusively or in combination with
formula for at least 6 months. §Used ≥ 80% of study medication. ¶Composite adverse neonatal outcome until 10 weeks after expected date
of delivery, containing following components: respiratory distress syndrome, bronchopulmonary dysplasia, intracerebral hemorrhage
> Grade II, necrotizing enterocolitis > Stage 1, proven sepsis and death before discharge. **Total number of children born < 37 weeks, i.e.
includes children born < 34 weeks and < 32 weeks. BSID-III, Bayley Scales of Infant and Toddler Development, third edition; GA, gesta-
tional age; NICU, neonatal intensive care unit; PPROM, preterm prelabor rupture of membranes.
© 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 57: 431–439.
on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
436 Cuijpers et al.
such as hemangioma, cafe-au-lait spot, color difference
between the two irises, ptosis in one eye, umbilical hernia
and small cardiac septal defect (Table 2). No consistent
differences in the type of congenital malformation could
be detected between the groups. No differences in genital
malformations or other health-related outcomes were seen
between the progesterone and placebo groups (Table 2).
There was one child with a genetic disorder, Noonan
syndrome, in the placebo group.
Composite abnormal developmental outcome
and mortality
Composite abnormal developmental outcome (consisting
of abnormal BSID-III or CBCL score or physical
impairment) was found in 5/29 (17%) children in the
progesterone group and 5/30 (17%) children in the
placebo group (OR, 0.97 (95% CI, 0.31–2.99)) (Table 3).
After multiple imputation, the composite abnormal
developmental outcome doubled in both groups, to 34%
in the progesterone group and 32% in the placebo group
(OR, 0.94 (95% CI, 0.45–1.99)), but remained similar
between the groups. Comparable results were found
when combining abnormal developmental outcome with
mortality in a multiple imputed dataset (Table 3).
DISCUSSION
In this 2-year follow-up study of a randomized clinical
trial comparing antenatal progesterone with placebo for
the prevention of preterm birth in low-risk women with
a mid-trimester short cervix, we found no significant
differences in neurodevelopmental outcomes assessed by
the Bayley-III scale. No differences were found in the
other physical, behavioral and health-related outcomes in
children at a corrected age of 2 years.
This study has several strengths. First, as it was
a follow-up study of a randomized controlled trial,
it was possible to maintain blinding of the parents,
care-providers and researchers to the treatment alloca-
tion during the follow-up measurements and data entry.
This prevented performance and detection bias. Second,
instead of parental reports only, this follow-up study used
a broad variety of validated instruments and assessments
such as the BSID-III test and neurological and physical
assessment by medical doctors. To our knowledge, only
Table 2 Neurodevelopmental, physical, behavioral and health-related infant outcomes at 2 years corrected age, according to whether they







difference (95% CI) P
BSID-III*
Cognitive composite score 101.6 ± 9.7 105.0 ± 12.5 –3.4 (–9.3 to 2.6) 0.29
Motor composite score 102.4 ± 10.9 107.3 ± 12.6 –4.9 (–11.2 to 1.4) 0.13
Fine motor mean scale scores 11.4 ± 2.3 12.8 ± 2.7 –1.4 (–2.7 to –0.9) 0.04
Gross motor score 9.2 ± 2.0 9.5 ± 2.2 –0.3 (–1.4 to 0.8) 0.58
Neurological examination
Mild abnormality 2/25 (8) 1/25 (4) 2.00 (0.19 to 20.67) 1.00
General physical examination†
Congenital abnormality 7/26 (27) 3/26 (12) 2.33 (0.68 to 8.05) 0.29
Minor‡ 6/26 (23) 3/26 (12) 2.00 (0.56 to 7.16) 0.47
Major§ 1/26 (4) 0/26 (0) — 1.00
Syndrome/genetic disorder† 0/27 (0) 1/27 (4) — 1.00
Genital abnormality¶ 3/26 (12) 3/25 (12) 0.96 (0.21 to 4.3) 1.00
Questionnaires
Abnormal ASQ** 5/27 (19) 5/27 (19) 1.00 (0.33 to 3.06) 1.00
Abnormal CBCL†† 1/27 (4) 4/27 (15) 0.22 (0.02 to 2.12) 0.35
General health
Need for healthcare providers additional to visits to
GP (developmental support and/or specialist care)
14/29 (48) 15/27 (56) 0.87 (0.52 to 1.44) 0.59
Use of any medication in 2 years after birth 21/29 (72) 22/27 (81) 0.89 (0.66 to 1.19) 0.42
At least two hospital admissions in 2 years after birth 2/29 (7) 2/25 (8) 0.86 (0.13 to 5.68) 1.00
At least two operations in 2 years after birth 0/29 (0) 1/27 (4) — 1.00
Data are given as mean ± SD or n/N (%). *Data available for: 29 infants in placebo group; 28 infants for cognitive composite score and fine
motor score and 27 infants for motor composite score and gross motor score in progesterone group. †Data available for: 27 infants in
placebo group; 27 infants in progesterone group. ‡Progesterone group: hemangioma (n = 1), combination of café-au-lait spot and small
cardiac septal defect (n = 1), combination of two dimples on back and café-au-lait spots (n = 1), depigmented small stripes on upper body
(n = 1), color differences between two irises (n = 1), small umbilical hernia (n = 1); placebo group: hemangioma (n = 1), isolated café-au-lait
spots (n = 1), ptosis in one eye (n = 1). §Combination of failure to thrive, need for percutaneous endoscopic gastrostomy tube and genital
abnormality (small testes and thin penis with normal length) with no known underlying genetic cause at time of writing. ¶Progesterone
group: small testes and thin penis with normal length (n = 1), café-au-lait spot of 5 cm on labia majora (n = 1), underdeveloped scrotal skin
(n = 1); placebo group: undescended testis (n = 1), unretractable foreskin (n = 1), labial adhesion to 70% of labium minus (n = 1). **Defined
as score 1 SD below normative mean on two or more domains, or as score of 2 SD below normative mean on at least one domain. ††Defined
as score in the clinical range (> 97th percentile). ASQ, Ages and Stages Questionnaire, third edition; BSID-III, Bayley Scales of Infant and
Toddler Development, third edition; CBCL, Child Behavior Checklist; GP, general practitioner; RR, relative risk.
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Table 3 Complete-case and multiple-imputation analyses for composite outcome of mortality and abnormal development in 80 infants
included in Triple P trial, from time of randomization until 2 years of corrected age
Outcome Progesterone Placebo Odds ratio (95% CI) P
Complete-case analysis
n 41 39
Neonatal death 1/41 (2) 2/39 (5) 0.46 (0.04–5.32) 0.53
Death up to 2 years of age 1/41 (2) 2/39 (5) 0.46 (0.04–5.32) 0.53
No follow-up 11/40 (28) 7/37 (19) 0.62 (0.21–1.80) 0.37
Assessment at 2 years of age
n 29 30
BSID-III (cognitive or motor)
≤–1 SD* 1/28 (4) 1/29(3) 1.04 (0.06–17.43) 1.00
≤–2 SD 0/28 (0) 0/29 (0) — —
Abnormal CBCL† 1/27 (4) 4/27 (15) 0.22 (0.02–2.12) 0.35
Physical problem‡ 3/29 (10) 2/27 (7) 1.44 (0.22–9.37) 1.00
Abnormal developmental outcome§ 5/29 (17) 5/30 (17) 0.97 (0.31–2.99) 1.00
Death or abnormal developmental outcome 6/41 (15) 7/39 (18) 0.78 (0.24–2.58) 0.69
Multiple imputation¶
n 41 39
BSID-III (cognitive or motor) ≤–1 SD* 6.4/40 (16) 4.7/37 (13) 0.77 (0.17–3.60) 0.74
Abnormal CBCL† 6.4/40 (16) 7.7/37 (21) 1.37 (0.41–4.55) 0.61
Physical problem‡ 3.8/40 (10) 4.3/37 (12) 1.17 (0.24–5.70) 0.85
Abnormal developmental outcome§ 13.4/40 (34) 11.7/37 (32) 0.94 (0.45–1.99) 0.87
Death or abnormal developmental outcome** 14.4/41 (35) 13.7/39 (35) 1.00 (0.50–1.98) 0.99
Data are given as n/N (%) unless otherwise indicated. *Normal or abnormal scores were based on mean score (100) and SD of predefined
reference group. Abnormal BSID-III is defined as score ≤ –1 SD below normative mean (100). †Defined as score in clinical range (> 97th
percentile). ‡Defined as at least two hospital admissions and/or at least two operations in 2 years after birth. §Composite of BSID-III score
≤–1 SD or CBCL score in clinical range or physical problem (at least two hospital admissions and/or at least two operations in 2 years after
birth). ¶Pooled outcomes of 10 imputed datasets. **Composite score of neonatal death (no imputed data) and abnormal developmental
outcome (with imputed data). BSID-III, Bayley Scales of Infant and Toddler Development, third edition; CBCL, Child Behavior Checklist.
one other randomized trial (the OPPTIMUM study5) has
reported BSID outcomes and also physical assessment
results in children exposed to progesterone vs placebo
during pregnancy. A third strength of our study is the rel-
atively long in-utero exposure to progesterone compared
with that of other studies. In the Triple P trial, women
started using daily progesterone at 22 weeks’ gestation and
were able to continue until 34 weeks, as the vast majority
of women delivered at term. Irrespective of differences
in compliance, children in our study had a potentially
longer in-utero exposure to progesterone than did those
in other studies3. This is important in case an association
between duration of in-utero exposure to progesterone
and potential harms or benefits is found in the future.
The main limitation of this study was the small number
of patients randomized in the original Triple P study and
therefore low statistical power to explore more subtle but
clinically relevant effects. Although this follow-up study
had enough power to detect a 1 SD (15 points) mean
difference in BSID-III scores between the two groups, it
is unlikely that such a large difference due to exposure
to progesterone would have been found. The study was
not powered to detect a smaller but clinically important
difference of 0.5 SD (7.5 points). The same holds true for
the other outcome measures reported. Another limitation
of the study is the loss to follow-up. Even though a total
follow-up rate of 77% (and 74% for BSID-III participants)
is quite high for a long-term follow-up study, there is a
risk of attrition bias. In this study, this is probably the
case, as there was a difference in parental education
and ethnicity between the participants of this follow-up
study and those who were lost to follow-up. The same
applies to neonatal adverse outcome, prematurity and
low birth weight though the difference was not significant
(Table S1). As these factors are strongly associated with
neurodevelopment25–28, the relatively ‘low-risk’ sample
at follow-up could have reduced differences between the
two groups. We tried to overcome this attrition bias by
performing multiple imputation, in which factors such as
education and ethnicity were used as predictors for the
imputed neurodevelopmental variables. It is therefore not
surprising that the multiple imputation analysis showed
a two-fold increase in the rate of neurodevelopmental
problems in both groups, reaching values similar to
the rates seen in the OPPTIMUM follow-up study5,
nevertheless there was no statistically significant difference
in this parameter between the placebo and progesterone
groups. Attrition bias is a limitation of most follow-up
studies and hampers the generalizability of results.
Prophylactic administration of vaginal progesterone is
a common practice globally for women with a history of
spontaneous PTB29. The use of progesterone for the pre-
vention of PTB in other populations (i.e. low-risk women
with a short cervix) is still debated, and variation in prac-
tice is high. The 2013 Cochrane review on progesterone
for the prevention of PTB concluded that there was a pos-
itive effect on neonatal outcome, but recommended that
obtaining long-term follow-up data should be a priority29.
This conclusion has become even more relevant with new
insights into the effects of progesterone on the developing
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brain in animal models14. Owing to its lipophilic struc-
ture, progesterone can cross the blood–brain barrier,
and it has been shown that it plays a role in neuronal
proliferation and differentiation, myelination and brain
sexual differentiation14. Our Triple P follow-up study
contributes to the knowledge of long-term infant out-
comes after in-utero exposure to progesterone.
Findings from the Triple P follow-up study are
consistent with previous follow-up studies showing no
significant signs of harm with respect to neurodevelop-
ment, hospitalization or mortality in children exposed
to progesterone compared with placebo4–8. However,
our findings do not confirm a significant increase in
renal, gastrointestinal or respiratory impairment found
in the secondary analysis of the OPPTIMUM trial
(e.g. renal-impairment RR, 3.65 (95% CI, 1.96–6.82)),
although with low absolute rates of 1 to 2%5. We were
also unable to confirm the 8-fold increased risk of cardiac
abnormalities reported in the follow-up study of the
PREDICT trial at 8 years of age8. The non-significant
4-fold decrease in abnormal CBCL scores in the pro-
gesterone group observed in our study has not been
reported in other follow-up studies, and was probably
caused by a type-I error related to our small sample size
and multiple testing. However, there is also a possibility
that it could be related to a potential neuroprotective
mechanism of progesterone in utero. If this were true,
the observed difference in behavioral problems between
the progesterone and placebo groups could be clinically
relevant and therefore valuable for hypothesis-generating
in future follow-up studies on the use of progesterone.
It remains possible that the potential impact of pro-
gesterone on the development of the brain has not been
revealed by the measurements used in previous follow-up
studies (including OPPTIMUM and our follow-up study),
as children might have been too young to study the pos-
sible side-effects of antenatal exposure to progesterone.
Developmental disabilities become more apparent at
around the age of 5 years, and are a better predictor
of performance in later life30,31. Therefore, we strongly
encourage researchers who carried out randomized trials
on progesterone to perform follow-up studies at later
ages using appropriate diagnostic outcome measures.
In conclusion, in mostly (near) term-born offspring
of women with a mid-pregnancy short cervix, physical,
behavioral and neurodevelopmental outcomes at a
corrected age of 2 years were not found to be different
between children exposed in utero to progesterone
vs those exposed to placebo. Antenatal exposure to
progesterone does not seem to indicate major concerns for
the neurodevelopment and health of infants at 2 years of
age. Our data should contribute to future meta-analyses
to increase confidence that progesterone can be considered
safe to use in the second and third trimesters of pregnancy.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Figure S1 Directed acyclic graphs of causal assumption in Triple P follow-up study.
Table S1 Pregnancy and neonatal outcomes and baseline characteristics of mothers and their children who
participated in Triple P follow-up study and those who were lost to follow-up
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